CINGCingulate Inc.
Is Cingulate struggling financially?
Yes, by its own account. Cingulate told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.
Going concern disclosed May 2026
30/100
Fragile
- Sector
- Biotech/Pharma
- Market cap
- $80.7M
- Source filing
- 10-Q 14 May 2026
- Balance sheet
- 30 Jun 2026
Cash runway
-
16months
If the burn speeds up
Empty by Oct 2027
-
23months
If it eases off
Empty by May 2028
Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.
Out of cashTwo years or more
The runway math
Cash and short-term investments
$28.4M
÷
Cash burned over the last 12 months
$17.4M
What Cingulate told the SEC
…plans will be effectively implemented in such a way that they will sufficiently alleviate or mitigate the conditions and events noted above, which results in substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The accompanying consolidated financial statements have been prepared on a going concern basis, which…
Cingulate Inc., Form 10-Q, filed 14 May 2026.
Read the filing on SEC.govWhat this means
- Not a bankruptcy filing, and not a prediction.
- It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
- The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.
What else the numbers show
- 185.5% share-count increase The company issued stock. Each share now owns 65.0% less of the business than a year ago, before any change in the price.
- Cash burn is narrowing It is spending 47% less cash per year than it was, so the runway above is lengthening rather than shortening.
Other Biotech/Pharma companies that filed the doubt
- DCOY Decoy Therapeutics $2.1M
- BJDX Bluejay Diagnostics $4.1M
- KTTA Pasithea Therapeutics $18.0M
- CABA Cabaletta Bio $530.7M
- TNXP Tonix Pharmaceuticals Holding $215.2M
- OCGN Ocugen $471.4M